Eloxx Pharmaceuticals (ELOX)
Develops ribosome-modulating medicines for nonsense-mutation kidney diseases.
Something off on this page? Send us feedback.
Develops ribosome-modulating medicines for patients with nonsense mutations, centered on injectable exaluren for genetic kidney disease. It has no approved products or product sales; proprietary value depends on clinical development and regulatory approval, while partnered rare-skin-disease economics depend on Almirall.
Develops ribosome-modulating small molecules for genetic diseases caused by nonsense mutations. Its proprietary candidate, exaluren, is an injectable treatment designed to restore full-length collagen in mutation-defined Alport syndrome and is also being planned for a subset of autosomal dominant polycystic kidney disease.
Operates across the United States, Israel, and Australia through a remote, lean organization that relies on contract research and manufacturing providers. An oral agent for rare skin diseases is licensed to Almirall; prospective partner milestones and royalties depend on Almirall's development, regulatory, and commercial execution. Exaluren development depends on clinical results, regulatory acceptance of endpoints, and enrollment of genetically eligible patients.
Company facts
Unavailable right now.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $62.0M · Total debt $0 · Total assets $63.4M · Shareholders' equity $46.4M
- Revenue
- $0
- Operating income
- −$4.5M
- Net income
- −$4.5M
No dividends on record.
| Institutions22 holders · as of Jun 30, 2026 | 61.93% | 2.50M shares | |
| Insiders2 holders · as of Aug 14, 2026 | 13.76% | 555.5K shares | |
| Strategic holders2 holders · as of Jul 27, 2026 | 31.09% | 1.25M shares | |
| Adds to | 106.78% |
4.04M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (4.04M in the company's Sep 3, 2026 report, 3.44M elsewhere); stakes use the report.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
These groups come from separate filings that can overlap, so they add to 106.78%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Domicilium Capital Partners LLCStrategic | 21.18% | 854,973 | 13Gfiled Jun 17, 2026 ↗ |
Coastlands Capital LPInstitution | 10.17% | 410,530 | 13Gfiled Jun 17, 2026 ↗ |
Abrdn PLCInstitution | 9.91% | 400,000 | 13Fas of Jun 30, 2026 |
Aberdeen Group plcStrategic | 9.91% | 400,000 | 13Gfiled Jul 27, 2026 ↗ |
Ecor1 Capital, LLCInstitution | 9.91% | 400,000 | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
Nothing filed in the last 12 months.
- Vertex Pharmaceuticals
Variant-targeted ADPKD program overlaps genetic patients.
- Novartis (ADR)
Phase 3 ADPKD program seeks disease modification at scale.
- Krystal Biotech
Approved topical gene therapy for dystrophic epidermolysis bullosa.
- Abeona Therapeutics
Approved RDEB gene therapy for severe wound treatment.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Eloxx Pharmaceuticals | $16.11 | +0.50% | $54.4M | — | — | — | — |
| Vertex Pharmaceuticals | $555.40 | −0.23% | $141.31B | 32.4 | 28.6 | 11.2 | +12.5% |
| Novartis (ADR) | $162.45 | +0.01% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Krystal Biotech | $375.00 | +1.53% | $10.88B | 46.3 | 43.5 | 24.7 | +24.1% |
| Abeona Therapeutics | $5.86 | −1.76% | $339.1M | — | — | 13.3 | +2,745.0% |
| Median | 32.4 | 28.6 | 12.2 | +18.3% |